Naloxone Drip in Opioid Overdose Management

Primary Indications

A continuous naloxone infusion is indicated for patients with opioid overdose who have persistent respiratory depression after initial bolus doses, particularly with long-acting opioids where the duration of opioid effect exceeds naloxone's duration of action, as recommended by the American Heart Association 1, 2
Respiratory depression from long-acting opioids (e.g., methadone) where the duration of opioid effect (several hours) exceeds naloxone's duration of action (45-70 minutes) 1, 3
Life-threatening central nervous system or respiratory depression that has been initially reversed with naloxone but is at risk for resedation 1

Initial bolus dosing should begin with 0.04-0.4 mg IV, with repeat dosing or dose escalation to 2 mg if the initial response is inadequate, according to the American Heart Association 1
For patients with therapeutic opioid use, lower initial doses (0.04-0.2 mg) may be considered to avoid complete reversal of analgesia 2
Some patients may require much higher doses to reverse intoxication with atypical opioids (such as propoxyphene) or following massive overdose 1

Begin with bag-mask ventilation to support breathing while preparing naloxone, as recommended by the American Heart Association 1, 3
Administer initial naloxone bolus (0.04-0.4 mg IV/IM/IN) 1, 2
If inadequate response, administer additional bolus doses until adequate respiratory function is achieved 1
If respiratory depression recurs or patient has taken a long-acting opioid, consider continuous naloxone infusion 1, 2

Monitor for signs of opioid withdrawal, which may include agitation, hypertension, and tachycardia 1, 3
Continue monitoring for at least 2 hours after discontinuation of the naloxone infusion 2

Naloxone has no effect on respiratory depression caused by non-opioid substances (e.g., benzodiazepines, alcohol) 4, 5
Patients with opioid dependence may experience precipitated withdrawal with naloxone administration, which can cause agitation, hypertension, and violent behavior 1, 3
The goal of naloxone administration should be improved ventilatory effort, not necessarily full awakening 5

For short-acting opioids like heroin or morphine, a brief period of observation may be appropriate after discontinuation of the infusion 1
For long-acting opioids like methadone, a longer period of observation is required to safely discharge the patient 1, 3

The American Heart Association, as published in Circulation, recommends that the decision to administer naloxone must balance the immediate need to reverse life-threatening respiratory depression against the risk of exacerbating intracerebral hemorrhage 6
The American Society of Anesthesiologists recommends confirming opioid-associated respiratory depression is the primary cause of respiratory compromise before administering naloxone 7

The American Heart Association, as published in Circulation, suggests using the lowest effective dose of naloxone (0.04-0.2 mg initially) to avoid complete reversal of analgesia and minimize withdrawal symptoms 6
The American Society of Anesthesiologists recommends maintaining intravenous access for medication administration and beginning with bag-mask ventilation to support breathing while preparing naloxone 7
The American Heart Association, as published in Circulation, advises titrating naloxone slowly with small incremental doses until adequate respiratory function is achieved and avoiding rapid or complete reversal of opioid effects 6
The American Society of Anesthesiologists suggests considering noninvasive positive-pressure ventilation to improve ventilatory status if appropriate, and supplemental oxygen should be administered to patients with altered level of consciousness, respiratory depression, or hypoxemia 7

The American Society of Anesthesiologists recommends continuous monitoring of vital signs, especially blood pressure, and close neurological monitoring for signs of increased intracranial pressure 7
The American Heart Association, as published in Circulation, advises an extended observation period (at least 2 hours after last naloxone dose) 6